Targeting cancer therapy in mice by use of newly developed immunoliposomes bearing adriamycin

Masaki Hirota, Kiyoyasu Fukushima, Kazuhito Hiratani, Junichi Kadota, Kenji Kawano, Mikio Oka, Akimitsu Tomonaga, Kohei Hara, Toshinori Sato, Junzo Sunamoto

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Polysaccharide-coated liposomes have been developed to improve the stability of conventional liposomes against biochemical and physicochemical stimuli. Pullulan (MW 5 × 104) was used as the polysaccharide. the mouse IgM monoclonal antibody (CSLEX 1) recognizes a sialosylated Lex, which is a tumor-specific antigen in athymic mice. the IgM antibody was reduced with cysteine to obtain the subunit (IgMs) that remained biologically active. the IgMs was accumulated in an antigen-positive tumor in vivo. Subsequently, it was conjugated with the pullulan-coated liposome to form an immunoliposome. Tissue distribution studies demonstrated that immunoliposomes were more efficiently targeted to an implanted tumor than to the polysaccharide-coated liposomes. This is accompanied by a drastic decrease in liver uptake of the immunoliposomes. Furthermore, adriamycin-encapsulated immunoliposomes in-hibited the growth of the implanted tumor more effectively than did the simple pulluian-coated liposomes.

Original languageEnglish
Pages (from-to)15-33
Number of pages19
JournalJournal of Liposome Research
Issue number1
Publication statusPublished - 1988
Externally publishedYes

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Targeting cancer therapy in mice by use of newly developed immunoliposomes bearing adriamycin'. Together they form a unique fingerprint.

Cite this